NCT01547728 - Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions

Thrombophilia Due to Acquired Antithrombin III Deficiency

Interventions

DRUG

Recombinant antithrombin (rhAT)

Subjects will receive an intravenous bolus of 500 units of recombinant, human antithrombin (rhAT, ATRYN ®). If the subject remains heparin-resistant, one more IV bolus of 500 units rhAT is given.

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester